Shijiazhuang Sihua Pharmaceutical’s Azithromycin Dry Suspension Receives First Domestic Approval
Category:
发布时间:2022-09-05
【概要描述】
Recently, the azithromycin dry suspension developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was granted a drug registration certificate by the National Medical Products Administration and is deemed to have passed the consistency evaluation, making it the first domestic pharmaceutical company to receive such approval.
Recently, the azithromycin dry suspension developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was granted a drug registration certificate by the National Medical Products Administration and is deemed to have passed the consistency evaluation, making it the first domestic pharmaceutical company to receive such approval.
According to reports, azithromycin dry suspension is a second-generation macrolide antibiotic primarily indicated for the treatment of lower respiratory tract infections such as bronchitis and pneumonia caused by susceptible bacteria, as well as skin and soft-tissue infections, acute otitis media and sinusitis, pharyngitis, and tonsillitis—conditions that constitute upper respiratory tract infections.
The approval of this azithromycin dry suspension will help the company diversify its dosage forms, optimize its product mix, accelerate supply-side structural transformation, and further promote high-quality corporate development. To date, Shijiazhuang Sihua Pharmaceutical Group has had a total of 27 drug varieties comprising 36 dosage forms either approved or deemed to have passed the National Evaluation of Quality and Therapeutic Equivalence for Generic Drugs.
Keywords:
Recommended News
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091